oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Effects of on outcomes: A systematic review and meta-analysis Oral Semaglutide and Cardiovascular Outcomes

On Wednesday, the FDA issued another warning calling these drugs risky and stating compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. How Can Hims & Hers Do This

Dehydration can lead to leg cramps, so keeping your body hydrated is essential

this warrants ongoing monitoring No unexpected serious cardiovascular signals were identified during the limited Phase 2 follow-up period, though the trials were neither designed nor powered to assess cardiovascular outcomes, and longer-term data are not yet available At present, the overall safety profile appears broadly consistent with other GLP-1-based therapies, but definitive conclusions cannot be drawn until Phase 3 data and post-marketing surveillance are available

Successful weight loss usually does not happen from a single appointment

In addition to appetite control, these medications may also slow the rate at which food leaves the stomach, further aiding in weight loss efforts